新規経口抗凝固剤（NOAC）の世界市場（～2026年）

• 英文タイトル：Global Novel Oral AntiCoagulants (NOAC) Market Insights and Forecast to 2026

• レポートコード：MRC2-11QY08240 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、148ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ
Enterprise License	￥1,154,400 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料は新規経口抗凝固剤（NOAC）のグローバル市場について調査・分析したレポートです。種類別（直接トロンビン阻害剤、直接第Xa因子阻害剤）市場規模、用途別（深部静脈血栓症（DVT）、肺塞栓症、急性冠症候群、血液透析、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別新規経口抗凝固剤（NOAC）の競争状況、市場シェア ・世界の新規経口抗凝固剤（NOAC）市場：種類別市場規模 2015年-2020年（直接トロンビン阻害剤、直接第Xa因子阻害剤） ・世界の新規経口抗凝固剤（NOAC）市場：種類別市場規模予測 2021年-2026年（直接トロンビン阻害剤、直接第Xa因子阻害剤） ・世界の新規経口抗凝固剤（NOAC）市場：用途別市場規模 2015年-2020年（深部静脈血栓症（DVT）、肺塞栓症、急性冠症候群、血液透析、その他） ・世界の新規経口抗凝固剤（NOAC）市場：用途別市場規模予測 2021年-2026年（深部静脈血栓症（DVT）、肺塞栓症、急性冠症候群、血液透析、その他） ・北米の新規経口抗凝固剤（NOAC）市場分析：米国、カナダ ・ヨーロッパの新規経口抗凝固剤（NOAC）市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの新規経口抗凝固剤（NOAC）市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の新規経口抗凝固剤（NOAC）市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの新規経口抗凝固剤（NOAC）市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Johnson & Johnson、Bristol-Myers Squibb、Boehringer Ingelheim、Sanofi、Daiichi Sankyo、Armatheon、Aspen、AstraZeneca、Bayer、Cellceutix、Cosmo Pharmaceuticals、CSL Behring、Eisai、GSK、Marathon Pharmaceuticals、Ockham Biotech、Perosphere ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論

Market Analysis and Insights: Global Novel Oral AntiCoagulants (NOAC) Market
The global Novel Oral AntiCoagulants (NOAC) market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Novel Oral AntiCoagulants (NOAC) Scope and Market Size
Novel Oral AntiCoagulants (NOAC) market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Novel Oral AntiCoagulants (NOAC) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

Segment by Type, the Novel Oral AntiCoagulants (NOAC) market is segmented into
Direct Thrombin Inhibitors
Direct Factor Xa Inhibitors

Segment by Application, the Novel Oral AntiCoagulants (NOAC) market is segmented into
Deep Vein Thrombosis (DVT)
Pulmonary Embolism
Acute Coronary Syndrome
Hemodialysis
Others

Regional and Country-level Analysis
The Novel Oral AntiCoagulants (NOAC) market is analysed and market size information is provided by regions (countries).
The key regions covered in the Novel Oral AntiCoagulants (NOAC) market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Novel Oral AntiCoagulants (NOAC) Market Share Analysis
Novel Oral AntiCoagulants (NOAC) market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Novel Oral AntiCoagulants (NOAC) business, the date to enter into the Novel Oral AntiCoagulants (NOAC) market, Novel Oral AntiCoagulants (NOAC) product introduction, recent developments, etc.

The major vendors covered:
Johnson & Johnson
Bristol-Myers Squibb
Boehringer Ingelheim
Sanofi
Daiichi Sankyo
Armatheon
Aspen
AstraZeneca
Bayer
Cellceutix
Cosmo Pharmaceuticals
CSL Behring
Eisai
GSK
Marathon Pharmaceuticals
Ockham Biotech
Perosphere

レポート目次

---

1 Study Coverage
1.1 Novel Oral AntiCoagulants (NOAC) Product Introduction
1.2 Market Segments
1.3 Key Novel Oral AntiCoagulants (NOAC) Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Novel Oral AntiCoagulants (NOAC) Market Size Growth Rate by Type
1.4.2 Direct Thrombin Inhibitors
1.4.3 Direct Factor Xa Inhibitors
1.5 Market by Application
1.5.1 Global Novel Oral AntiCoagulants (NOAC) Market Size Growth Rate by Application
1.5.2 Deep Vein Thrombosis (DVT)
1.5.3 Pulmonary Embolism
1.5.4 Acute Coronary Syndrome
1.5.5 Hemodialysis
1.5.6 Others
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Novel Oral AntiCoagulants (NOAC) Market Size, Estimates and Forecasts
2.1.1 Global Novel Oral AntiCoagulants (NOAC) Revenue 2015-2026
2.1.2 Global Novel Oral AntiCoagulants (NOAC) Sales 2015-2026
2.2 Global Novel Oral AntiCoagulants (NOAC), Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Novel Oral AntiCoagulants (NOAC) Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Novel Oral AntiCoagulants (NOAC) Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Novel Oral AntiCoagulants (NOAC) Competitor Landscape by Players
3.1 Novel Oral AntiCoagulants (NOAC) Sales by Manufacturers
3.1.1 Novel Oral AntiCoagulants (NOAC) Sales by Manufacturers (2015-2020)
3.1.2 Novel Oral AntiCoagulants (NOAC) Sales Market Share by Manufacturers (2015-2020)
3.2 Novel Oral AntiCoagulants (NOAC) Revenue by Manufacturers
3.2.1 Novel Oral AntiCoagulants (NOAC) Revenue by Manufacturers (2015-2020)
3.2.2 Novel Oral AntiCoagulants (NOAC) Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Novel Oral AntiCoagulants (NOAC) Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Novel Oral AntiCoagulants (NOAC) Revenue in 2019
3.2.5 Global Novel Oral AntiCoagulants (NOAC) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Novel Oral AntiCoagulants (NOAC) Price by Manufacturers
3.4 Novel Oral AntiCoagulants (NOAC) Manufacturing Base Distribution, Product Types
3.4.1 Novel Oral AntiCoagulants (NOAC) Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Novel Oral AntiCoagulants (NOAC) Product Type
3.4.3 Date of International Manufacturers Enter into Novel Oral AntiCoagulants (NOAC) Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Novel Oral AntiCoagulants (NOAC) Market Size by Type (2015-2020)
4.1.1 Global Novel Oral AntiCoagulants (NOAC) Sales by Type (2015-2020)
4.1.2 Global Novel Oral AntiCoagulants (NOAC) Revenue by Type (2015-2020)
4.1.3 Novel Oral AntiCoagulants (NOAC) Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Novel Oral AntiCoagulants (NOAC) Market Size Forecast by Type (2021-2026)
4.2.1 Global Novel Oral AntiCoagulants (NOAC) Sales Forecast by Type (2021-2026)
4.2.2 Global Novel Oral AntiCoagulants (NOAC) Revenue Forecast by Type (2021-2026)
4.2.3 Novel Oral AntiCoagulants (NOAC) Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Novel Oral AntiCoagulants (NOAC) Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)
5.1 Global Novel Oral AntiCoagulants (NOAC) Market Size by Application (2015-2020)
5.1.1 Global Novel Oral AntiCoagulants (NOAC) Sales by Application (2015-2020)
5.1.2 Global Novel Oral AntiCoagulants (NOAC) Revenue by Application (2015-2020)
5.1.3 Novel Oral AntiCoagulants (NOAC) Price by Application (2015-2020)
5.2 Novel Oral AntiCoagulants (NOAC) Market Size Forecast by Application (2021-2026)
5.2.1 Global Novel Oral AntiCoagulants (NOAC) Sales Forecast by Application (2021-2026)
5.2.2 Global Novel Oral AntiCoagulants (NOAC) Revenue Forecast by Application (2021-2026)
5.2.3 Global Novel Oral AntiCoagulants (NOAC) Price Forecast by Application (2021-2026)

6 North America
6.1 North America Novel Oral AntiCoagulants (NOAC) by Country
6.1.1 North America Novel Oral AntiCoagulants (NOAC) Sales by Country
6.1.2 North America Novel Oral AntiCoagulants (NOAC) Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Novel Oral AntiCoagulants (NOAC) Market Facts & Figures by Type
6.3 North America Novel Oral AntiCoagulants (NOAC) Market Facts & Figures by Application

7 Europe
7.1 Europe Novel Oral AntiCoagulants (NOAC) by Country
7.1.1 Europe Novel Oral AntiCoagulants (NOAC) Sales by Country
7.1.2 Europe Novel Oral AntiCoagulants (NOAC) Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Novel Oral AntiCoagulants (NOAC) Market Facts & Figures by Type
7.3 Europe Novel Oral AntiCoagulants (NOAC) Market Facts & Figures by Application

8 Asia Pacific
8.1 Asia Pacific Novel Oral AntiCoagulants (NOAC) by Region
8.1.1 Asia Pacific Novel Oral AntiCoagulants (NOAC) Sales by Region
8.1.2 Asia Pacific Novel Oral AntiCoagulants (NOAC) Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Novel Oral AntiCoagulants (NOAC) Market Facts & Figures by Type
8.3 Asia Pacific Novel Oral AntiCoagulants (NOAC) Market Facts & Figures by Application

9 Latin America
9.1 Latin America Novel Oral AntiCoagulants (NOAC) by Country
9.1.1 Latin America Novel Oral AntiCoagulants (NOAC) Sales by Country
9.1.2 Latin America Novel Oral AntiCoagulants (NOAC) Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Novel Oral AntiCoagulants (NOAC) Market Facts & Figures by Type
9.3 Central & South America Novel Oral AntiCoagulants (NOAC) Market Facts & Figures by Application

10 Middle East and Africa
10.1 Middle East and Africa Novel Oral AntiCoagulants (NOAC) by Country
10.1.1 Middle East and Africa Novel Oral AntiCoagulants (NOAC) Sales by Country
10.1.2 Middle East and Africa Novel Oral AntiCoagulants (NOAC) Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Novel Oral AntiCoagulants (NOAC) Market Facts & Figures by Type
10.3 Middle East and Africa Novel Oral AntiCoagulants (NOAC) Market Facts & Figures by Application

11 Company Profiles
11.1 Johnson & Johnson
11.1.1 Johnson & Johnson Corporation Information
11.1.2 Johnson & Johnson Description and Business Overview
11.1.3 Johnson & Johnson Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Johnson & Johnson Novel Oral AntiCoagulants (NOAC) Products Offered
11.1.5 Johnson & Johnson Related Developments
11.2 Bristol-Myers Squibb
11.2.1 Bristol-Myers Squibb Corporation Information
11.2.2 Bristol-Myers Squibb Description and Business Overview
11.2.3 Bristol-Myers Squibb Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Bristol-Myers Squibb Novel Oral AntiCoagulants (NOAC) Products Offered
11.2.5 Bristol-Myers Squibb Related Developments
11.3 Boehringer Ingelheim
11.3.1 Boehringer Ingelheim Corporation Information
11.3.2 Boehringer Ingelheim Description and Business Overview
11.3.3 Boehringer Ingelheim Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Boehringer Ingelheim Novel Oral AntiCoagulants (NOAC) Products Offered
11.3.5 Boehringer Ingelheim Related Developments
11.4 Sanofi
11.4.1 Sanofi Corporation Information
11.4.2 Sanofi Description and Business Overview
11.4.3 Sanofi Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Sanofi Novel Oral AntiCoagulants (NOAC) Products Offered
11.4.5 Sanofi Related Developments
11.5 Daiichi Sankyo
11.5.1 Daiichi Sankyo Corporation Information
11.5.2 Daiichi Sankyo Description and Business Overview
11.5.3 Daiichi Sankyo Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Daiichi Sankyo Novel Oral AntiCoagulants (NOAC) Products Offered
11.5.5 Daiichi Sankyo Related Developments
11.6 Armatheon
11.6.1 Armatheon Corporation Information
11.6.2 Armatheon Description and Business Overview
11.6.3 Armatheon Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Armatheon Novel Oral AntiCoagulants (NOAC) Products Offered
11.6.5 Armatheon Related Developments
11.7 Aspen
11.7.1 Aspen Corporation Information
11.7.2 Aspen Description and Business Overview
11.7.3 Aspen Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Aspen Novel Oral AntiCoagulants (NOAC) Products Offered
11.7.5 Aspen Related Developments
11.8 AstraZeneca
11.8.1 AstraZeneca Corporation Information
11.8.2 AstraZeneca Description and Business Overview
11.8.3 AstraZeneca Sales, Revenue and Gross Margin (2015-2020)
11.8.4 AstraZeneca Novel Oral AntiCoagulants (NOAC) Products Offered
11.8.5 AstraZeneca Related Developments
11.9 Bayer
11.9.1 Bayer Corporation Information
11.9.2 Bayer Description and Business Overview
11.9.3 Bayer Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Bayer Novel Oral AntiCoagulants (NOAC) Products Offered
11.9.5 Bayer Related Developments
11.10 Cellceutix
11.10.1 Cellceutix Corporation Information
11.10.2 Cellceutix Description and Business Overview
11.10.3 Cellceutix Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Cellceutix Novel Oral AntiCoagulants (NOAC) Products Offered
11.10.5 Cellceutix Related Developments
11.1 Johnson & Johnson
11.1.1 Johnson & Johnson Corporation Information
11.1.2 Johnson & Johnson Description and Business Overview
11.1.3 Johnson & Johnson Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Johnson & Johnson Novel Oral AntiCoagulants (NOAC) Products Offered
11.1.5 Johnson & Johnson Related Developments
11.12 CSL Behring
11.12.1 CSL Behring Corporation Information
11.12.2 CSL Behring Description and Business Overview
11.12.3 CSL Behring Sales, Revenue and Gross Margin (2015-2020)
11.12.4 CSL Behring Products Offered
11.12.5 CSL Behring Related Developments
11.13 Eisai
11.13.1 Eisai Corporation Information
11.13.2 Eisai Description and Business Overview
11.13.3 Eisai Sales, Revenue and Gross Margin (2015-2020)
11.13.4 Eisai Products Offered
11.13.5 Eisai Related Developments
11.14 GSK
11.14.1 GSK Corporation Information
11.14.2 GSK Description and Business Overview
11.14.3 GSK Sales, Revenue and Gross Margin (2015-2020)
11.14.4 GSK Products Offered
11.14.5 GSK Related Developments
11.15 Marathon Pharmaceuticals
11.15.1 Marathon Pharmaceuticals Corporation Information
11.15.2 Marathon Pharmaceuticals Description and Business Overview
11.15.3 Marathon Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.15.4 Marathon Pharmaceuticals Products Offered
11.15.5 Marathon Pharmaceuticals Related Developments
11.16 Ockham Biotech
11.16.1 Ockham Biotech Corporation Information
11.16.2 Ockham Biotech Description and Business Overview
11.16.3 Ockham Biotech Sales, Revenue and Gross Margin (2015-2020)
11.16.4 Ockham Biotech Products Offered
11.16.5 Ockham Biotech Related Developments
11.17 Perosphere
11.17.1 Perosphere Corporation Information
11.17.2 Perosphere Description and Business Overview
11.17.3 Perosphere Sales, Revenue and Gross Margin (2015-2020)
11.17.4 Perosphere Products Offered
11.17.5 Perosphere Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Novel Oral AntiCoagulants (NOAC) Market Estimates and Projections by Region
12.1.1 Global Novel Oral AntiCoagulants (NOAC) Sales Forecast by Regions 2021-2026
12.1.2 Global Novel Oral AntiCoagulants (NOAC) Revenue Forecast by Regions 2021-2026
12.2 North America Novel Oral AntiCoagulants (NOAC) Market Size Forecast (2021-2026)
12.2.1 North America: Novel Oral AntiCoagulants (NOAC) Sales Forecast (2021-2026)
12.2.2 North America: Novel Oral AntiCoagulants (NOAC) Revenue Forecast (2021-2026)
12.2.3 North America: Novel Oral AntiCoagulants (NOAC) Market Size Forecast by Country (2021-2026)
12.3 Europe Novel Oral AntiCoagulants (NOAC) Market Size Forecast (2021-2026)
12.3.1 Europe: Novel Oral AntiCoagulants (NOAC) Sales Forecast (2021-2026)
12.3.2 Europe: Novel Oral AntiCoagulants (NOAC) Revenue Forecast (2021-2026)
12.3.3 Europe: Novel Oral AntiCoagulants (NOAC) Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Novel Oral AntiCoagulants (NOAC) Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Novel Oral AntiCoagulants (NOAC) Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Novel Oral AntiCoagulants (NOAC) Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Novel Oral AntiCoagulants (NOAC) Market Size Forecast by Region (2021-2026)
12.5 Latin America Novel Oral AntiCoagulants (NOAC) Market Size Forecast (2021-2026)
12.5.1 Latin America: Novel Oral AntiCoagulants (NOAC) Sales Forecast (2021-2026)
12.5.2 Latin America: Novel Oral AntiCoagulants (NOAC) Revenue Forecast (2021-2026)
12.5.3 Latin America: Novel Oral AntiCoagulants (NOAC) Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Novel Oral AntiCoagulants (NOAC) Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Novel Oral AntiCoagulants (NOAC) Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Novel Oral AntiCoagulants (NOAC) Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Novel Oral AntiCoagulants (NOAC) Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Novel Oral AntiCoagulants (NOAC) Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Novel Oral AntiCoagulants (NOAC) Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer

List of Tables
Table 1. Novel Oral AntiCoagulants (NOAC) Market Segments
Table 2. Ranking of Global Top Novel Oral AntiCoagulants (NOAC) Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Novel Oral AntiCoagulants (NOAC) Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of Direct Thrombin Inhibitors
Table 5. Major Manufacturers of Direct Factor Xa Inhibitors
Table 6. Global Novel Oral AntiCoagulants (NOAC) Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 7. Global Novel Oral AntiCoagulants (NOAC) Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 8. Global Novel Oral AntiCoagulants (NOAC) Sales by Regions 2015-2020 (K Pcs)
Table 9. Global Novel Oral AntiCoagulants (NOAC) Sales Market Share by Regions (2015-2020)
Table 10. Global Novel Oral AntiCoagulants (NOAC) Revenue by Regions 2015-2020 (US$ Million)
Table 11. Global Novel Oral AntiCoagulants (NOAC) Sales by Manufacturers (2015-2020) (K Pcs)
Table 12. Global Novel Oral AntiCoagulants (NOAC) Sales Share by Manufacturers (2015-2020)
Table 13. Global Novel Oral AntiCoagulants (NOAC) Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 14. Global Novel Oral AntiCoagulants (NOAC) by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Novel Oral AntiCoagulants (NOAC) as of 2019)
Table 15. Novel Oral AntiCoagulants (NOAC) Revenue by Manufacturers (2015-2020) (US$ Million)
Table 16. Novel Oral AntiCoagulants (NOAC) Revenue Share by Manufacturers (2015-2020)
Table 17. Key Manufacturers Novel Oral AntiCoagulants (NOAC) Price (2015-2020) (USD/Pcs)
Table 18. Novel Oral AntiCoagulants (NOAC) Manufacturers Manufacturing Base Distribution and Headquarters
Table 19. Manufacturers Novel Oral AntiCoagulants (NOAC) Product Type
Table 20. Date of International Manufacturers Enter into Novel Oral AntiCoagulants (NOAC) Market
Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 22. Global Novel Oral AntiCoagulants (NOAC) Sales by Type (2015-2020) (K Pcs)
Table 23. Global Novel Oral AntiCoagulants (NOAC) Sales Share by Type (2015-2020)
Table 24. Global Novel Oral AntiCoagulants (NOAC) Revenue by Type (2015-2020) (US$ Million)
Table 25. Global Novel Oral AntiCoagulants (NOAC) Revenue Share by Type (2015-2020)
Table 26. Novel Oral AntiCoagulants (NOAC) Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 27. Global Novel Oral AntiCoagulants (NOAC) Sales by Application (2015-2020) (K Pcs)
Table 28. Global Novel Oral AntiCoagulants (NOAC) Sales Share by Application (2015-2020)
Table 29. North America Novel Oral AntiCoagulants (NOAC) Sales by Country (2015-2020) (K Pcs)
Table 30. North America Novel Oral AntiCoagulants (NOAC) Sales Market Share by Country (2015-2020)
Table 31. North America Novel Oral AntiCoagulants (NOAC) Revenue by Country (2015-2020) (US$ Million)
Table 32. North America Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Country (2015-2020)
Table 33. North America Novel Oral AntiCoagulants (NOAC) Sales by Type (2015-2020) (K Pcs)
Table 34. North America Novel Oral AntiCoagulants (NOAC) Sales Market Share by Type (2015-2020)
Table 35. North America Novel Oral AntiCoagulants (NOAC) Sales by Application (2015-2020) (K Pcs)
Table 36. North America Novel Oral AntiCoagulants (NOAC) Sales Market Share by Application (2015-2020)
Table 37. Europe Novel Oral AntiCoagulants (NOAC) Sales by Country (2015-2020) (K Pcs)
Table 38. Europe Novel Oral AntiCoagulants (NOAC) Sales Market Share by Country (2015-2020)
Table 39. Europe Novel Oral AntiCoagulants (NOAC) Revenue by Country (2015-2020) (US$ Million)
Table 40. Europe Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Country (2015-2020)
Table 41. Europe Novel Oral AntiCoagulants (NOAC) Sales by Type (2015-2020) (K Pcs)
Table 42. Europe Novel Oral AntiCoagulants (NOAC) Sales Market Share by Type (2015-2020)
Table 43. Europe Novel Oral AntiCoagulants (NOAC) Sales by Application (2015-2020) (K Pcs)
Table 44. Europe Novel Oral AntiCoagulants (NOAC) Sales Market Share by Application (2015-2020)
Table 45. Asia Pacific Novel Oral AntiCoagulants (NOAC) Sales by Region (2015-2020) (K Pcs)
Table 46. Asia Pacific Novel Oral AntiCoagulants (NOAC) Sales Market Share by Region (2015-2020)
Table 47. Asia Pacific Novel Oral AntiCoagulants (NOAC) Revenue by Region (2015-2020) (US$ Million)
Table 48. Asia Pacific Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Region (2015-2020)
Table 49. Asia Pacific Novel Oral AntiCoagulants (NOAC) Sales by Type (2015-2020) (K Pcs)
Table 50. Asia Pacific Novel Oral AntiCoagulants (NOAC) Sales Market Share by Type (2015-2020)
Table 51. Asia Pacific Novel Oral AntiCoagulants (NOAC) Sales by Application (2015-2020) (K Pcs)
Table 52. Asia Pacific Novel Oral AntiCoagulants (NOAC) Sales Market Share by Application (2015-2020)
Table 53. Latin America Novel Oral AntiCoagulants (NOAC) Sales by Country (2015-2020) (K Pcs)
Table 54. Latin America Novel Oral AntiCoagulants (NOAC) Sales Market Share by Country (2015-2020)
Table 55. Latin Americaa Novel Oral AntiCoagulants (NOAC) Revenue by Country (2015-2020) (US$ Million)
Table 56. Latin America Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Country (2015-2020)
Table 57. Latin America Novel Oral AntiCoagulants (NOAC) Sales by Type (2015-2020) (K Pcs)
Table 58. Latin America Novel Oral AntiCoagulants (NOAC) Sales Market Share by Type (2015-2020)
Table 59. Latin America Novel Oral AntiCoagulants (NOAC) Sales by Application (2015-2020) (K Pcs)
Table 60. Latin America Novel Oral AntiCoagulants (NOAC) Sales Market Share by Application (2015-2020)
Table 61. Middle East and Africa Novel Oral AntiCoagulants (NOAC) Sales by Country (2015-2020) (K Pcs)
Table 62. Middle East and Africa Novel Oral AntiCoagulants (NOAC) Sales Market Share by Country (2015-2020)
Table 63. Middle East and Africa Novel Oral AntiCoagulants (NOAC) Revenue by Country (2015-2020) (US$ Million)
Table 64. Middle East and Africa Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Country (2015-2020)
Table 65. Middle East and Africa Novel Oral AntiCoagulants (NOAC) Sales by Type (2015-2020) (K Pcs)
Table 66. Middle East and Africa Novel Oral AntiCoagulants (NOAC) Sales Market Share by Type (2015-2020)
Table 67. Middle East and Africa Novel Oral AntiCoagulants (NOAC) Sales by Application (2015-2020) (K Pcs)
Table 68. Middle East and Africa Novel Oral AntiCoagulants (NOAC) Sales Market Share by Application (2015-2020)
Table 69. Johnson & Johnson Corporation Information
Table 70. Johnson & Johnson Description and Major Businesses
Table 71. Johnson & Johnson Novel Oral AntiCoagulants (NOAC) Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 72. Johnson & Johnson Product
Table 73. Johnson & Johnson Recent Development
Table 74. Bristol-Myers Squibb Corporation Information
Table 75. Bristol-Myers Squibb Description and Major Businesses
Table 76. Bristol-Myers Squibb Novel Oral AntiCoagulants (NOAC) Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 77. Bristol-Myers Squibb Product
Table 78. Bristol-Myers Squibb Recent Development
Table 79. Boehringer Ingelheim Corporation Information
Table 80. Boehringer Ingelheim Description and Major Businesses
Table 81. Boehringer Ingelheim Novel Oral AntiCoagulants (NOAC) Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 82. Boehringer Ingelheim Product
Table 83. Boehringer Ingelheim Recent Development
Table 84. Sanofi Corporation Information
Table 85. Sanofi Description and Major Businesses
Table 86. Sanofi Novel Oral AntiCoagulants (NOAC) Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 87. Sanofi Product
Table 88. Sanofi Recent Development
Table 89. Daiichi Sankyo Corporation Information
Table 90. Daiichi Sankyo Description and Major Businesses
Table 91. Daiichi Sankyo Novel Oral AntiCoagulants (NOAC) Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 92. Daiichi Sankyo Product
Table 93. Daiichi Sankyo Recent Development
Table 94. Armatheon Corporation Information
Table 95. Armatheon Description and Major Businesses
Table 96. Armatheon Novel Oral AntiCoagulants (NOAC) Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 97. Armatheon Product
Table 98. Armatheon Recent Development
Table 99. Aspen Corporation Information
Table 100. Aspen Description and Major Businesses
Table 101. Aspen Novel Oral AntiCoagulants (NOAC) Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 102. Aspen Product
Table 103. Aspen Recent Development
Table 104. AstraZeneca Corporation Information
Table 105. AstraZeneca Description and Major Businesses
Table 106. AstraZeneca Novel Oral AntiCoagulants (NOAC) Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 107. AstraZeneca Product
Table 108. AstraZeneca Recent Development
Table 109. Bayer Corporation Information
Table 110. Bayer Description and Major Businesses
Table 111. Bayer Novel Oral AntiCoagulants (NOAC) Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 112. Bayer Product
Table 113. Bayer Recent Development
Table 114. Cellceutix Corporation Information
Table 115. Cellceutix Description and Major Businesses
Table 116. Cellceutix Novel Oral AntiCoagulants (NOAC) Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 117. Cellceutix Product
Table 118. Cellceutix Recent Development
Table 119. Cosmo Pharmaceuticals Corporation Information
Table 120. Cosmo Pharmaceuticals Description and Major Businesses
Table 121. Cosmo Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 122. Cosmo Pharmaceuticals Product
Table 123. Cosmo Pharmaceuticals Recent Development
Table 124. CSL Behring Corporation Information
Table 125. CSL Behring Description and Major Businesses
Table 126. CSL Behring Novel Oral AntiCoagulants (NOAC) Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 127. CSL Behring Product
Table 128. CSL Behring Recent Development
Table 129. Eisai Corporation Information
Table 130. Eisai Description and Major Businesses
Table 131. Eisai Novel Oral AntiCoagulants (NOAC) Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 132. Eisai Product
Table 133. Eisai Recent Development
Table 134. GSK Corporation Information
Table 135. GSK Description and Major Businesses
Table 136. GSK Novel Oral AntiCoagulants (NOAC) Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 137. GSK Product
Table 138. GSK Recent Development
Table 139. Marathon Pharmaceuticals Corporation Information
Table 140. Marathon Pharmaceuticals Description and Major Businesses
Table 141. Marathon Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 142. Marathon Pharmaceuticals Product
Table 143. Marathon Pharmaceuticals Recent Development
Table 144. Ockham Biotech Corporation Information
Table 145. Ockham Biotech Description and Major Businesses
Table 146. Ockham Biotech Novel Oral AntiCoagulants (NOAC) Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 147. Ockham Biotech Product
Table 148. Ockham Biotech Recent Development
Table 149. Perosphere Corporation Information
Table 150. Perosphere Description and Major Businesses
Table 151. Perosphere Novel Oral AntiCoagulants (NOAC) Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 152. Perosphere Product
Table 153. Perosphere Recent Development
Table 154. Global Novel Oral AntiCoagulants (NOAC) Sales Forecast by Regions (2021-2026) (K Pcs)
Table 155. Global Novel Oral AntiCoagulants (NOAC) Sales Market Share Forecast by Regions (2021-2026)
Table 156. Global Novel Oral AntiCoagulants (NOAC) Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 157. Global Novel Oral AntiCoagulants (NOAC) Revenue Market Share Forecast by Regions (2021-2026)
Table 158. North America: Novel Oral AntiCoagulants (NOAC) Sales Forecast by Country (2021-2026) (K Pcs)
Table 159. North America: Novel Oral AntiCoagulants (NOAC) Revenue Forecast by Country (2021-2026) (US$ Million)
Table 160. Europe: Novel Oral AntiCoagulants (NOAC) Sales Forecast by Country (2021-2026) (K Pcs)
Table 161. Europe: Novel Oral AntiCoagulants (NOAC) Revenue Forecast by Country (2021-2026) (US$ Million)
Table 162. Asia Pacific: Novel Oral AntiCoagulants (NOAC) Sales Forecast by Region (2021-2026) (K Pcs)
Table 163. Asia Pacific: Novel Oral AntiCoagulants (NOAC) Revenue Forecast by Region (2021-2026) (US$ Million)
Table 164. Latin America: Novel Oral AntiCoagulants (NOAC) Sales Forecast by Country (2021-2026) (K Pcs)
Table 165. Latin America: Novel Oral AntiCoagulants (NOAC) Revenue Forecast by Country (2021-2026) (US$ Million)
Table 166. Middle East and Africa: Novel Oral AntiCoagulants (NOAC) Sales Forecast by Country (2021-2026) (K Pcs)
Table 167. Middle East and Africa: Novel Oral AntiCoagulants (NOAC) Revenue Forecast by Country (2021-2026) (US$ Million)
Table 168. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 169. Key Challenges
Table 170. Market Risks
Table 171. Main Points Interviewed from Key Novel Oral AntiCoagulants (NOAC) Players
Table 172. Novel Oral AntiCoagulants (NOAC) Customers List
Table 173. Novel Oral AntiCoagulants (NOAC) Distributors List
Table 174. Research Programs/Design for This Report
Table 175. Key Data Information from Secondary Sources
Table 176. Key Data Information from Primary Sources
List of Figures
Figure 1. Novel Oral AntiCoagulants (NOAC) Product Picture
Figure 2. Global Novel Oral AntiCoagulants (NOAC) Sales Market Share by Type in 2020 & 2026
Figure 3. Direct Thrombin Inhibitors Product Picture
Figure 4. Direct Factor Xa Inhibitors Product Picture
Figure 5. Global Novel Oral AntiCoagulants (NOAC) Sales Market Share by Application in 2020 & 2026
Figure 6. Deep Vein Thrombosis (DVT)
Figure 7. Pulmonary Embolism
Figure 8. Acute Coronary Syndrome
Figure 9. Hemodialysis
Figure 10. Others
Figure 11. Novel Oral AntiCoagulants (NOAC) Report Years Considered
Figure 12. Global Novel Oral AntiCoagulants (NOAC) Market Size 2015-2026 (US$ Million)
Figure 13. Global Novel Oral AntiCoagulants (NOAC) Sales 2015-2026 (K Pcs)
Figure 14. Global Novel Oral AntiCoagulants (NOAC) Market Size Market Share by Region: 2020 Versus 2026
Figure 15. Global Novel Oral AntiCoagulants (NOAC) Sales Market Share by Region (2015-2020)
Figure 16. Global Novel Oral AntiCoagulants (NOAC) Sales Market Share by Region in 2019
Figure 17. Global Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Region (2015-2020)
Figure 18. Global Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Region in 2019
Figure 19. Global Novel Oral AntiCoagulants (NOAC) Sales Share by Manufacturer in 2019
Figure 20. The Top 10 and 5 Players Market Share by Novel Oral AntiCoagulants (NOAC) Revenue in 2019
Figure 21. Novel Oral AntiCoagulants (NOAC) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 22. Global Novel Oral AntiCoagulants (NOAC) Sales Market Share by Type (2015-2020)
Figure 23. Global Novel Oral AntiCoagulants (NOAC) Sales Market Share by Type in 2019
Figure 24. Global Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Type (2015-2020)
Figure 25. Global Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Type in 2019
Figure 26. Global Novel Oral AntiCoagulants (NOAC) Market Share by Price Range (2015-2020)
Figure 27. Global Novel Oral AntiCoagulants (NOAC) Sales Market Share by Application (2015-2020)
Figure 28. Global Novel Oral AntiCoagulants (NOAC) Sales Market Share by Application in 2019
Figure 29. Global Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Application (2015-2020)
Figure 30. Global Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Application in 2019
Figure 31. North America Novel Oral AntiCoagulants (NOAC) Sales Growth Rate 2015-2020 (K Pcs)
Figure 32. North America Novel Oral AntiCoagulants (NOAC) Revenue Growth Rate 2015-2020 (US$ Million)
Figure 33. North America Novel Oral AntiCoagulants (NOAC) Sales Market Share by Country in 2019
Figure 34. North America Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Country in 2019
Figure 35. U.S. Novel Oral AntiCoagulants (NOAC) Sales Growth Rate (2015-2020) (K Pcs)
Figure 36. U.S. Novel Oral AntiCoagulants (NOAC) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 37. Canada Novel Oral AntiCoagulants (NOAC) Sales Growth Rate (2015-2020) (K Pcs)
Figure 38. Canada Novel Oral AntiCoagulants (NOAC) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 39. North America Novel Oral AntiCoagulants (NOAC) Market Share by Type in 2019
Figure 40. North America Novel Oral AntiCoagulants (NOAC) Market Share by Application in 2019
Figure 41. Europe Novel Oral AntiCoagulants (NOAC) Sales Growth Rate 2015-2020 (K Pcs)
Figure 42. Europe Novel Oral AntiCoagulants (NOAC) Revenue Growth Rate 2015-2020 (US$ Million)
Figure 43. Europe Novel Oral AntiCoagulants (NOAC) Sales Market Share by Country in 2019
Figure 44. Europe Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Country in 2019
Figure 45. Germany Novel Oral AntiCoagulants (NOAC) Sales Growth Rate (2015-2020) (K Pcs)
Figure 46. Germany Novel Oral AntiCoagulants (NOAC) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 47. France Novel Oral AntiCoagulants (NOAC) Sales Growth Rate (2015-2020) (K Pcs)
Figure 48. France Novel Oral AntiCoagulants (NOAC) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. U.K. Novel Oral AntiCoagulants (NOAC) Sales Growth Rate (2015-2020) (K Pcs)
Figure 50. U.K. Novel Oral AntiCoagulants (NOAC) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. Italy Novel Oral AntiCoagulants (NOAC) Sales Growth Rate (2015-2020) (K Pcs)
Figure 52. Italy Novel Oral AntiCoagulants (NOAC) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Russia Novel Oral AntiCoagulants (NOAC) Sales Growth Rate (2015-2020) (K Pcs)
Figure 54. Russia Novel Oral AntiCoagulants (NOAC) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Europe Novel Oral AntiCoagulants (NOAC) Market Share by Type in 2019
Figure 56. Europe Novel Oral AntiCoagulants (NOAC) Market Share by Application in 2019
Figure 57. Asia Pacific Novel Oral AntiCoagulants (NOAC) Sales Growth Rate 2015-2020 (K Pcs)
Figure 58. Asia Pacific Novel Oral AntiCoagulants (NOAC) Revenue Growth Rate 2015-2020 (US$ Million)
Figure 59. Asia Pacific Novel Oral AntiCoagulants (NOAC) Sales Market Share by Region in 2019
Figure 60. Asia Pacific Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Region in 2019
Figure 61. China Novel Oral AntiCoagulants (NOAC) Sales Growth Rate (2015-2020) (K Pcs)
Figure 62. China Novel Oral AntiCoagulants (NOAC) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 63. Japan Novel Oral AntiCoagulants (NOAC) Sales Growth Rate (2015-2020) (K Pcs)
Figure 64. Japan Novel Oral AntiCoagulants (NOAC) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. South Korea Novel Oral AntiCoagulants (NOAC) Sales Growth Rate (2015-2020) (K Pcs)
Figure 66. South Korea Novel Oral AntiCoagulants (NOAC) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. India Novel Oral AntiCoagulants (NOAC) Sales Growth Rate (2015-2020) (K Pcs)
Figure 68. India Novel Oral AntiCoagulants (NOAC) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. Australia Novel Oral AntiCoagulants (NOAC) Sales Growth Rate (2015-2020) (K Pcs)
Figure 70. Australia Novel Oral AntiCoagulants (NOAC) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Taiwan Novel Oral AntiCoagulants (NOAC) Sales Growth Rate (2015-2020) (K Pcs)
Figure 72. Taiwan Novel Oral AntiCoagulants (NOAC) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Indonesia Novel Oral AntiCoagulants (NOAC) Sales Growth Rate (2015-2020) (K Pcs)
Figure 74. Indonesia Novel Oral AntiCoagulants (NOAC) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Thailand Novel Oral AntiCoagulants (NOAC) Sales Growth Rate (2015-2020) (K Pcs)
Figure 76. Thailand Novel Oral AntiCoagulants (NOAC) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Malaysia Novel Oral AntiCoagulants (NOAC) Sales Growth Rate (2015-2020) (K Pcs)
Figure 78. Malaysia Novel Oral AntiCoagulants (NOAC) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Philippines Novel Oral AntiCoagulants (NOAC) Sales Growth Rate (2015-2020) (K Pcs)
Figure 80. Philippines Novel Oral AntiCoagulants (NOAC) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Vietnam Novel Oral AntiCoagulants (NOAC) Sales Growth Rate (2015-2020) (K Pcs)
Figure 82. Vietnam Novel Oral AntiCoagulants (NOAC) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Asia Pacific Novel Oral AntiCoagulants (NOAC) Market Share by Type in 2019
Figure 84. Asia Pacific Novel Oral AntiCoagulants (NOAC) Market Share by Application in 2019
Figure 85. Latin America Novel Oral AntiCoagulants (NOAC) Sales Growth Rate 2015-2020 (K Pcs)
Figure 86. Latin America Novel Oral AntiCoagulants (NOAC) Revenue Growth Rate 2015-2020 (US$ Million)
Figure 87. Latin America Novel Oral AntiCoagulants (NOAC) Sales Market Share by Country in 2019
Figure 88. Latin America Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Country in 2019
Figure 89. Mexico Novel Oral AntiCoagulants (NOAC) Sales Growth Rate (2015-2020) (K Pcs)
Figure 90. Mexico Novel Oral AntiCoagulants (NOAC) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 91. Brazil Novel Oral AntiCoagulants (NOAC) Sales Growth Rate (2015-2020) (K Pcs)
Figure 92. Brazil Novel Oral AntiCoagulants (NOAC) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Argentina Novel Oral AntiCoagulants (NOAC) Sales Growth Rate (2015-2020) (K Pcs)
Figure 94. Argentina Novel Oral AntiCoagulants (NOAC) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 95. Latin America Novel Oral AntiCoagulants (NOAC) Market Share by Type in 2019
Figure 96. Latin America Novel Oral AntiCoagulants (NOAC) Market Share by Application in 2019
Figure 97. Middle East and Africa Novel Oral AntiCoagulants (NOAC) Sales Growth Rate 2015-2020 (K Pcs)
Figure 98. Middle East and Africa Novel Oral AntiCoagulants (NOAC) Revenue Growth Rate 2015-2020 (US$ Million)
Figure 99. Middle East and Africa Novel Oral AntiCoagulants (NOAC) Sales Market Share by Country in 2019
Figure 100. Middle East and Africa Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Country in 2019
Figure 101. Turkey Novel Oral AntiCoagulants (NOAC) Sales Growth Rate (2015-2020) (K Pcs)
Figure 102. Turkey Novel Oral AntiCoagulants (NOAC) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 103. Saudi Arabia Novel Oral AntiCoagulants (NOAC) Sales Growth Rate (2015-2020) (K Pcs)
Figure 104. Saudi Arabia Novel Oral AntiCoagulants (NOAC) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. U.A.E Novel Oral AntiCoagulants (NOAC) Sales Growth Rate (2015-2020) (K Pcs)
Figure 106. U.A.E Novel Oral AntiCoagulants (NOAC) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 107. Middle East and Africa Novel Oral AntiCoagulants (NOAC) Market Share by Type in 2019
Figure 108. Middle East and Africa Novel Oral AntiCoagulants (NOAC) Market Share by Application in 2019
Figure 109. North America Novel Oral AntiCoagulants (NOAC) Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 110. North America Novel Oral AntiCoagulants (NOAC) Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 111. Europe Novel Oral AntiCoagulants (NOAC) Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 112. Europe Novel Oral AntiCoagulants (NOAC) Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 113. Asia Pacific Novel Oral AntiCoagulants (NOAC) Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 114. Asia Pacific Novel Oral AntiCoagulants (NOAC) Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 115. Latin America Novel Oral AntiCoagulants (NOAC) Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 116. Latin America Novel Oral AntiCoagulants (NOAC) Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 117. Middle East and Africa Novel Oral AntiCoagulants (NOAC) Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 118. Middle East and Africa Novel Oral AntiCoagulants (NOAC) Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 119. Porter's Five Forces Analysis
Figure 120. Channels of Distribution
Figure 121. Distributors Profiles
Figure 122. Bottom-up and Top-down Approaches for This Report
Figure 123. Data Triangulation
Figure 124. Key Executives Interviewed

---